The link between abdominal obesity, metabolic syndrome and cardiovascular disease

WHO, 1999

Balkau, 1999, Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diabet Med, 16, 442, 10.1046/j.1464-5491.1999.00059.x

2001, Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

Bloomgarden, 2003, American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25–26 August 2002, Washington, DC, Diabetes Care, 26, 933, 10.2337/diacare.26.3.933

Alberti, 2005, The metabolic syndrome—a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8

Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404

Eckel, 2005, The Metabolic Syndrome, Lancet, 365, 1415, 10.1016/S0140-6736(05)66378-7

Cameron, 2004, The metabolic syndrome: prevalence in worldwide populations, Endocrinol Metab Clin North Am, 33, 351, 10.1016/j.ecl.2004.03.005

Ford, 2005, Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S., Diabetes Care, 28, 2745, 10.2337/diacare.28.11.2745

Ford, 2002, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 10.1001/jama.287.3.356

Miccoli, 2005, Prevalence of the metabolic syndrome among Italian adults according to ATP III definition, Nutr Metab Cardiovasc Dis, 15, 250, 10.1016/j.numecd.2004.09.002

Bigaard, 2005, Waist circumference and body composition in relation to all-cause mortality in middle-aged men and women, Int J Obes (Lond), 29, 778, 10.1038/sj.ijo.0802976

Hu, 2004, Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women, Arch Intern Med, 164, 1066, 10.1001/archinte.164.10.1066

Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683

McNeill, 2005, The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study, Diabetes Care, 28, 385, 10.2337/diacare.28.2.385

Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94

Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A Comparison of the NCEP ATPIII, IDF and AHA/NHBLI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: Evidence for sex-specific differences. Atherosclerosis 2006 Apr 6 [Epub ahead of print].

De Backer, 2003, European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts), Eur J Cardiovasc Prev Rehabil, 10, S1, 10.1097/00149831-200308000-00004

Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207

Pickup, 2004, Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes, Diabetes Care, 27, 813, 10.2337/diacare.27.3.813

Hotamisligil, 1993, Adipose expression of tumour necrosis factor-alpha: direct role in obesity induced inflammation, Science, 259, 87, 10.1126/science.7678183

Pasqui, 2005, Structural and functional abnormality of systemic microvessels in cardiac syndrome X., Nutr Metab Cardiovasc Dis, 15, 56, 10.1016/j.numecd.2004.05.001

Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, 352, 1685, 10.1056/NEJMra043430

Harrison, 1997, Cellular and molecular mechanisms of endothelial cell dysfunction, J Clin Invest, 100, 2153, 10.1172/JCI119751

Diamant, 2005, The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes, J Clin Endocrinol Metab, 90, 1495, 10.1210/jc.2004-1579

Xu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance, J Clin Invest, 112, 1821, 10.1172/JCI200319451

Mohanty, 2002, Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells, Am J Clin Nutr, 75, 722, 10.1093/ajcn/75.4.767

Aljada, 2004, Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for an inflammatory effect, Am J Clin Nutr, 79, 682, 10.1093/ajcn/79.4.682

Dandona, 2005, Metabolic Syndrome: A comprehensive perspective based on interaction between obesity, diabetes and inflammation, Circ, 111, 1448, 10.1161/01.CIR.0000158483.13093.9D

Petrie, 1996, Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease, Circulation, 93, 1331, 10.1161/01.CIR.93.7.1331

Ritchie, 2004, The role of insulin and the adipocytokines in regulation of vascular endothelial function, Clin Sci (Lond), 107, 519, 10.1042/CS20040190

Steinberg, 1996, Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance, J Clin Invest, 97, 2601, 10.1172/JCI118709

Cleland, 2000, Insulin action is associated with endothelial function in hypertension and type 2 diabetes, Hypertension, 35, 507, 10.1161/01.HYP.35.1.507

Hutley, 2005, Fat as an endocrine organ: Relationship to the Metabolic Syndrome, Am J Med Sci, 330, 280, 10.1097/00000441-200512000-00005

Pittas, 2004, Adipocytokines and insulin resistance, J Clin Endocrinol Metab, 89, 447, 10.1210/jc.2003-031005

Goldstein, 2004, Adiponectin: A novel adipokine linking adipocytes and vascular function, J Clin Endocrinol Metab, 89, 2563, 10.1210/jc.2004-0518

Hotamisligil, 1999, The role of TNF-alpha and TNF receptors in obesity and insulin resistance, J Intern Med, 245, 621, 10.1046/j.1365-2796.1999.00490.x

Rask-Madsen, 2003, Tumour necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans, Circulation, 108, 1815, 10.1161/01.CIR.0000091406.72832.11

Hotamisligil, 2003, Inflammatory pathways and insulin action, Int J Obesity, 27, S53, 10.1038/sj.ijo.0802502

Bastard, 2002, Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro, J Clin Endocrinol Metab, 87, 2084, 10.1210/jc.87.5.2084

Orshal, 2004, Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats, Hypertension, 43, 434, 10.1161/01.HYP.0000113044.46326.98

Cai, 2005, Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB, Nat Med, 11, 183, 10.1038/nm1166

Arkan, 2005, IKK-beta links inflammation to obesity-induced insulin resistance, Nat Med, 11, 191, 10.1038/nm1185

Nakatani, 2004, Modulation of the JNK pathway in liver affects insulin resistance status, J Biol Chem, 279, 45803, 10.1074/jbc.M406963200

Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255

Shimabukuro, 2003, Hypoadiponectinaemia is closely linked to endothelial dysfunction in man, J Clin Endocrinol Metab, 88, 3236, 10.1210/jc.2002-021883

Ryo, 2004, Adiponectin as a biomarker of the Metabolic syndrome, Circ J, 68, 975, 10.1253/circj.68.975

Pischon, 2004, Plasma Adiponectin and risk of myocardial infarction in men, JAMA, 291, 1730, 10.1001/jama.291.14.1730

Saha, 2004, Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo, Biochem Biophys Res Commun, 314, 580, 10.1016/j.bbrc.2003.12.120

Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505

Kato, 2006, Adiponectin acts as an endogenous antithrombotic factor, Arterioscler Thromb Vasc Biol, 26, 224, 10.1161/01.ATV.0000194076.84568.81

Lindsay, 2005, Adiponectin and coronary heart disease: the Strong Heart Study, Arterioscler Thromb Vasc Biol, 25, e15, 10.1161/01.ATV.0000153090.21990.8c

Chen, 2005, Hypoadiponectinaemia is associated with ischemic cerebrovascular disease, Arterioscler Thromb Vasc Biol, 25, 821, 10.1161/01.ATV.0000157784.25920.a7

Schulze, 2005, Adiponectin and future coronary heart disease events among men with type 2 diabetes, Diabetes, 54, 534, 10.2337/diabetes.54.2.534

Ouchi, 2000, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a cAMP-dependent pathway, Circulation, 102, 1296, 10.1161/01.CIR.102.11.1296

Wyne, 2003, Free fatty acids and type 2 diabetes mellitus, Am J Med, 115, 29S, 10.1016/j.amjmed.2003.09.004

Laaksonen, 2005, Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study, Diabetes, 54, 158, 10.2337/diabetes.54.1.158

Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512

Gill, 2006, Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity, Clinical Science, 110, 409, 10.1042/CS20050207

Ziccardi, 2002, Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year, Circulation, 105, 804, 10.1161/hc0702.104279

Brook, 2004, Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults, Am J Cardiol, 93, 1012, 10.1016/j.amjcard.2004.01.009

Filippatos, 2005, A review of the metabolic effects of sibutramine, Curr Med Res Opin, 21, 457, 10.1185/030079905X38132

Wadden, 2005, Randomized trial of lifestyle modification and pharmacotherapy for obesity, N Engl J Med, 353, 2111, 10.1056/NEJMoa050156

Hanusch-Enserer, 2004, Improvement of insulin resistance and early atherosclerosis in patients after gastric banding, Obes Res, 12, 284, 10.1038/oby.2004.36

Lichtman, 2005, Food for thought: endocannabinoid modulation of lipogenesis, J Clin Invest, 115, 1130, 10.1172/JCI25076

Van Gaal, 2005, Effect of rimonabant on weight reduction and cardiovascular risk, Lancet, 366, 369, 10.1016/S0140-6736(05)67020-1

Despres, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537

Kaneto, 2004, Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide, Nat Med, 10, 1128, 10.1038/nm1111

Prattali, 2005, Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals, FEBS Lett, 579, 3152, 10.1016/j.febslet.2005.04.075